Etanercept SFP in RA Patients

Inclusion Criteria: * Men and women 18 years of age or older who have RA, as defined by the ACR criteria for classification of RA * Naïve to etanercept therapy * Able to self-inject investigational product or have a designee who can do so * Ethical - Before any study-specific procedure, the appropriate written informed consent must be obtained Exclusion Criteria * Receipt of Corticosteroids\> 10 mg/day of prednisone (or its equivalent) during 14 days befor 1st dose of investigational product * Receipt of MTX witin 30 days of 1st dose of investigational product * Receipt of an other investigational drug within 30 days of 1st dose * Receipt of TNF inhibitor therapy within 90 days of 1st dose * Receipt of cyclophosphamide within 6 mo of 1st dose * Current use of nonsteroidal anti-inflammatory drugs (NSAIDs) greather than the maximum recommended dose in the product info sheet * Current use of insulin * gnificant concurrent medical condition